Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $44K rose 131.6% year over year, ahead of the +109.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 300.0% from the prior quarter. Over 3 fiscal years it compounded at +119.0% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +131.6% holds above the trailing-twelve-month pace of +109.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 105K USD
- Year-over-year change
- +87.5%
- 3-year CAGR
- +119.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105K | +87.5% |
| FY2024 | 2024-12-31 | 56K | +194.7% |
| FY2023 | 2023-12-31 | 19K | +90.0% |
| FY2022 | 2022-12-31 | 10K | — |
Depreciation & Amortization vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's LTM Mar 2026 depreciation & amortization of $130K is the 5th highest of the 6 companies compared; the peer median is $314K.
- Its year-over-year change of +109.7% is the 2nd highest of 6, against a peer median of -5.1%.
- Over three fiscal years its annual growth of +119.0% compares with a peer median of -8.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $1.12M | -32.0% | -8.2% | — | |
| LTM Mar 2026 | $314K | +2.6% | +49.5% | — | |
| LTM Mar 2026 | $148K | -99.6% | -26.0% | 1.2% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $130K | +109.7% | +119.0% | — |
| LTM Mar 2026 | $48.3K | +290.5% | +20.6% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $314K | -5.1% | -8.2% | 2.9% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 31.31M | 30.62M | 63.62M | 125.1M |
| Selling, General & Admin | 6.34M | 9.27M | 18.77M | 30.51M |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 155.6M |
| Depreciation & Amortization | 10K | 19K | 56K | 105K |
| EBITDA | (37.72M) | (51.96M) | (67.75M) | (137.63M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (37.66M) | (39.89M) | (82.39M) | (155.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 4K | 1.31M | 14.58M | 17.87M |
| Interest Expense | 112K | 0 | 0 | 0 |
| Other Income / Expenses | (188K) | (12.09M) | 14.58M | 17.87M |
| Income Before Tax | (37.84M) | (51.98M) | (67.81M) | (137.73M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 5K | 187K | 217K |
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.73) | (1.00) | (1.25) | (2.52) |
| EPS (Diluted) | (0.73) | (1.00) | (1.25) | (2.52) |
| Weighted Avg Shares | 51.76M | 51.76M | 54.42M | 54.68M |
| Weighted Avg Shares (Diluted) | 51.76M | 51.76M | 54.42M | 54.68M |
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.